Ozmosi | AK-132 Drug Profile
Contact Us
Drug Profile
Using advanced filters...
Advanced Search [+]

AK-132

Alternative Names: AK-132, AK 132, AK132
Clinical Status: Active
Latest Update: 2024-11-07
Latest Update Note: News Article

Product Description

anti-CLDN18.2 and CD47 Bispecific Antibody. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT06166472)

Mechanisms of Action: CLDN18.2 Inhibitor, CD47 Inhibitor

Novel Mechanism: Yes

Modality: Bispecific Antibody

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Akeso Pharm
Company Location: Asia Pacific
Company Founding Year: 2012
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AK-132

Countries in Clinic: China

Active Clinical Trial Count: 2

Recent & Upcoming Milestones

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT06166472

 AK132-101

P1

Not yet recruiting

Oncology Solid Tumor Unspecified

2026-04-24

67%

2023-12-13

CTR20233835

 CTR20233835

P1

Recruiting

Oncology Solid Tumor Unspecified

None

2025-04-29

Patient Enrollment|Start Date|Treatments|Trial Status

Recent News Events

Date

Type

Title

11/07/2024

News Article

 Akeso Published Mechanism of Action for CLDN18.2/CD47 Bispecific Antibody AK132 for the First Time at SITC Annual Meeting

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions